Treatment for Refractory Pancreatic Cancer
Abstract
While gemcitabine-based regimens are currently accepted as the standard first-line treatment of patients with locally advanced or metastatic pancreatic adenocarcinoma, there is no consensus regarding treatment in the second-line setting. This review is an update from the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #237 and #272 of the meeting.
Image: Sophia Engastromenou Schliemann (the founder of the "Sotiria"/"Salvation" Hospital) wearing the "Jewels of Helen" (photograph taken ca. 1874).
Downloads
References
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300. [PMID 20610543]
Li J, Saif MW. Advancements in the management of pancreatic cancer. JOP. J Pancreas (Online) 2009; 10:109-117. [PMID 19287102]
Brus C, Saif MW. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP. J Pancreas (Online) 2010; 11:321-3. [PMID 20601802]
Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, et al. Oxaliplatin/folinic acid/5-fluorouracil (24h (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005; 23(16 Suppl.):Abstract 4031.
Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Gorner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26(15 Suppl.):Abstract 4508.
Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010; 33:461-4. [PMID 20142727]
Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481-5. [PMID 16434988]
Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 2009; 76:333-7. [PMID 19307739]
Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046-52. [PMID 18756532]
Mane J, Iruarrizaga E, Rubio I, Fonseca E, Iza R, Casas I, et al. Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC).2011 Gastrointestinal Cancers Symposium. J Clin Oncol 2011; 29(Suppl. 4):Abstract 308.
Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11:635-638. [PMID 11081455]
Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 2010; 30:2905-9. [PMID 20683031]
Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67:93-7. [PMID 15539911]
Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY et al. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Invest New Drugs 2010; 28:343-9. [PMID 19444385]
Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658-63. [PMID 19826418]
Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 2010; 40:567-72. [PMID 20189975]
Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, et al. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol 2010; 40:774-80. [PMID 20462979]
Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, et al. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010; 66:1051-1057. [PMID 20130876]
Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009; 27:193-8. [PMID 19047305]
O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, et al. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010; 15:1310-9. [PMID 21148613]
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, et al. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol 2011; 34:70-75. [PMID 20458210]
Ko AH, Tempero MA, Shan Y, Su W, Lin Y, Dito E, et al. A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer. 2011 Gastrointestinal Cancers Symposium. J Clin Oncol 2011; 29(Suppl. 4):Abstract 237.
Chen L, Chang T, Cheng A, Yang C, Shiah H, Chang J, Yeh G. Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients. J Clin Oncol 2008; 26(15 Suppl.):Abstract 2565.
Chen L, Shiah H, Chao T, Hsieh K, Chen G, Chang J, Yeh G. Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors. J Clin Oncol 2010; 28(15 Supp.):Abstract e13024.
Taieb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 2007; 18:498-503. [PMID 17158774]
Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefevre L, Raymond E, et al. FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients. 2011 Gastrointestinal Cancers Symposium. J Clin Oncol 2011; 29(Suppl. 4):Abstract 272.
Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009; 63:1141-5. [PMID 18839175]
Copyright (c) 2011 Nektaria Makrilia, Kostas N Syrigos, Muhammad W Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.